PAVmed披露子公司Lucid Diagnostics完成1,500万美元优先股发行

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 21, 2026

Registrant’s telephone number, including area code: (917) 813-1828

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

Effective as of October 21, 2026, Lucid Diagnostics Inc. (the “Lucid Diagnostics”), a subsidiary of PAVmed Inc. (the “Company”), entered into subscription agreements (each, a “Subscription Agreement”) with certain accredited investors (collectively, the “Investors”), which agreements provided for the sale to the Investors of 15,000 shares of Lucid Diagnostics’ newly designated Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”), at a purchase price of $1,000 per share (collectively, the “Offering”). The closing of the transactions occurred on the same day. The gross proceeds to Lucid Diagnostics of the Offering were $15.0 million.

On the date of the closing, Lucid Diagnostics filed with the Secretary of State of the State of Delaware a Certificate of Designations of Preferences, Rights and Limitations of the Series C Preferred, which sets forth the resolutions of Lucid Diagnostics’ board of directors designating 15,000 shares of Series C Preferred Stock and fixing its terms.

Lucid Diagnostics and the Investors also executed a registration rights agreement, pursuant to which Lucid Diagnostics agreed to file a registration statement covering the resale of the shares of Lucid Diagnostics’ common stock issuable pursuant to the Series C Preferred Stock.

The Offering, including the related agreements and certificates, are described in more detail in the Current Report on Form 8-K filed by Lucid Diagnostics on October 22, 2026 (the “Lucid Diagnostics 8-K”), and such description is incorporated herein by reference.

Item 3.03. Material Modification to Rights of Security Holders.

The information included in Item 3.02 and Item 5.03 of the Lucid Diagnostics 8-K is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

(1) Incorporated by reference to Exhibit 10.1 of the Lucid Diagnostics 8-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.